terazosin has been researched along with dexniguldipine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borden, LA; Branchek, TA; Forray, C; Gluchowski, C; Miao, SW; Wetzel, JM | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
1 review(s) available for terazosin and dexniguldipine
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
2 other study(ies) available for terazosin and dexniguldipine
| Article | Year |
|---|---|
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Calcium Channel Blockers; Cell Line; Cloning, Molecular; Dihydropyridines; Humans; Receptors, Adrenergic, alpha-1 | 1995 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |